Therapy Detail

Therapy Name AR-42
Therapy Description

AR-42 is a histone deacetylase (HDAC) inhibitor, which may lead to increased apoptosis of tumor cells and decreased tumor growth (PMID: 23178755, PMID: 21778190).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AR-42 HDAC42 HDAC Inhibitor 34 AR-42 is a histone deacetylase (HDAC) inhibitor, which may lead to increased apoptosis of tumor cells and decreased tumor growth (PMID: 23178755, PMID: 21778190).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FBXW7 inact mut Advanced Solid Tumor sensitive AR-42 Preclinical Actionable In a preclinical study, AR-42 inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
Unknown unknown colon cancer not applicable AR-42 Preclinical - Cell line xenograft Actionable In a preclinical study, AR-42 induced cell death in primary human colon cancer cells and cell lines in culture, and inhibited tumor growth in colon cancer cell line xenograft models (PMID: 26026677). 26026677
FBXW7 inact mut hematologic cancer sensitive AR-42 Preclinical Actionable In a preclinical study, AR-42 inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). 23274910
Unknown unknown meningioma not applicable AR-42 Preclinical Actionable In a preclinical study, AR-42 induced apoptosis and inhibited proliferation of meningioma cells in culture (PMID: 21778190). 21778190
Clinical Trial Phase Therapies Title Recruitment Status
NCT02282917 Phase I AR-42 Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma Active, not recruiting